Joel Thompson is the new composer-in-residence for the New Haven Symphony Orchestra through June 2023.
Music Director Alasdair Neale said the NHSO has a long-standing commitment to playing and commissioning music by living composers.
“As someone living and working in New Haven, he will create new works of art in response to the joys and challenges of the people who make up our community,” Neale said.
Thompson is a conductor, pianist and educator whose works have been performed by the Atlanta Symphony Orchestra, Tallahassee Symphony Orchestra, Atlanta Master Chorale, Los Angeles Master Chorale, EXIGENCE and the San Francisco Gay Men’s Chorus.
Thompson’s best-known choral work, Seven Last Words of the Unarmed, earned him the 2018 American Prize for Choral Composition. He is currently a doctoral student at the Yale School of Music.
*****
TapestryHealth names new CEO
TapestryHealth, a Stratford-based company, has announced that Mark Hirschhorn, a member of its board of directors since April 2020, has been appointed CEO.
Before joining the Tapestry board, Hirschhorn served as CFO and COO of Teladoc Health from 2012 to 2019. Hirschhorn has also served as president and COO of TalkSpace, an online therapy service.
TapestryHealth provides healthcare services, both in-person and via telehealth technology, in nursing homes and independent and assisted-living communities.
Hirschhorn noted that the company is operating in over three dozen states and hundreds of facilities.
“We plan on concentrating growth and forging deeper relationships with each of our partner facilities,” he said. “We have a great foundation and a proven track record which signals a very strong future for the company”.
Dr. David Chess, Tapestry’s founder, indicated he sees Hirschhorn’s arrival as the next step in the company’s trajectory.
“His deep understanding of telemedicine system development, business scaling and managing the operations of complex organizations, coupled with his skills as a leader and financier makes Mark the perfect fit,” Chess said.
*****
BioXcel Therapeutics appoints SVP, chief commercial officer
BioXcel Therapeutics Inc., a New Haven-based biopharmaceutical company, has appointed Matt Wiley as its new senior vice president and chief commercial officer.
Wiley joins BioXcel from VYNE Therapeutics, where he oversaw all commercial objectives related to the launch of the company’s first two approved dermatology products. He has also had roles at Jazz Pharmaceuticals, Azur Pharma, Cephalon, Salix Pharmaceuticals and MGI Pharma.
CEO Vimal Mehta said the company is pleased to welcome Wiley to its management team as it prepares for its first potential approval and commercial launch of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders.
Mehta noted Wiley has more than 25 years of commercial and industry experience, including involvement in multiple product launches.
“Matt will be invaluable in spearheading critical launch initiatives, as well as the planned expansion of BXCL501 in additional indications, settings, and geographies, helping us maximize the potential of our AI-driven pipeline and R&D capabilities,” Mehta said.
*****
Rallybio names new lead communications, investor relations head
Rallybio Corp., a New Haven-based clinical-stage biotechnology company, has hired Ami Bavishi as the company’s head of investor relations and corporate communications.
Bavishi brings more than 10 years of experience to Rallybio. She will be responsible for overseeing Rallybio’s investor relations and communications efforts and strategies.
She will report to Steven Tuch, the company’s head of corporate development. Prior to joining Rallybio, Bavishi had similar roles with Aerie Pharmaceuticals Inc. and Burns McClellan.
